Oral CELMoD Golcadomide Advances in Relapsed FL

In an interview with Targeted Oncology at the 2026 European Hematology Association (EHA) Congress, Daniel Morillo, MD, START Madrid at Fundación Jiménez Díaz Quiron Salud Hospital, discusses long-term findings from the first-in-human phase 1/2 study of golcadomide (NCT03930953), an investigational oral cereblon E3 ligase modulator (CELMoD), in combination with rituximab (Rituxan) for patients with relapsed/refractory follicular lymphoma.

Shifting to results, Morillo first highlights the encouraging efficacy data presented at EHA, including the activity observed with the 0.4-mg dose of golcadomide plus rituximab which achieved a 97% overall response rate and a 75% complete response rate. He also emphasizes the durability of these responses, noting that most patients who achieved a complete response remained in remission 18 months later. While cautioning against cross-trial comparisons with rituximab plus lenalidomide (Revlimid), he explains how the ongoing phase 3 GOLSEEK-4 trial (NCT06911502) will provide a direct comparison between the regimens.

Morillo also reviews the safety profile, describing neutropenia as the most common grade 3 or higher adverse event but emphasizing that it was transient, manageable with granulocyte colony-stimulating factor support, and not associated with high rates of serious infections or febrile neutropenia. He concludes by discussing the limited nonhematologic toxicity observed with golcadomide, including the absence of a routine need for thromboprophylaxis, a potential differentiating feature compared with lenalidomide-based therapy.